Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$33.32 USD
-0.20 (-0.60%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $33.38 +0.06 (0.18%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Harmony Biosciences Holdings, Inc. (HRMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$45.11 | $59.00 | $28.00 | 30.49% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Harmony Biosciences Holdings, Inc. comes to $45.11. The forecasts range from a low of $28.00 to a high of $59.00. The average price target represents an increase of 30.49% from the last closing price of $34.57.
Analyst Price Targets (9 )
Broker Rating
Harmony Biosciences Holdings, Inc. currently has an average brokerage recommendation (ABR) of 1.89 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 6 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.00 | 1.89 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/21/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/12/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
4/9/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
3/28/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
2/16/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
1/9/2024 | Goldman Sachs | Corinne Johnson | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 1.89 |
# of Recs in ABR | 8 |
Average Target Price | $43.38 |
LT Growth Rate | 22.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 252 |
Current Quarter EPS Est: | -0.04 |